Medifast (MED) to Release Quarterly Earnings on Monday

Medifast (NYSE:MED) is anticipated to announce its Q3 2025 results after the market closes on Monday, November 3rd. Analysts expect Medifast to post earnings of ($0.01) per share and revenue of $84.10 million for the quarter. Medifast has set its Q3 2025 guidance at -0.600-0.00 EPS.Interested persons may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Monday, November 3, 2025 at 4:30 PM ET.

Medifast (NYSE:MED) last released its earnings results on Monday, August 4th. The specialty retailer reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.26. Medifast had a return on equity of 2.00% and a net margin of 0.76%.The firm had revenue of $105.56 million for the quarter, compared to analyst estimates of $96.10 million. On average, analysts expect Medifast to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Medifast Trading Up 0.5%

Shares of NYSE MED opened at $12.55 on Monday. Medifast has a twelve month low of $11.57 and a twelve month high of $21.98. The firm has a 50-day moving average of $13.71 and a two-hundred day moving average of $13.55. The company has a market capitalization of $137.92 million, a price-to-earnings ratio of 39.21 and a beta of 0.85.

Institutional Trading of Medifast

A number of hedge funds have recently bought and sold shares of the company. Bank of America Corp DE boosted its holdings in shares of Medifast by 37.4% in the second quarter. Bank of America Corp DE now owns 396,369 shares of the specialty retailer’s stock worth $5,569,000 after buying an additional 107,854 shares during the period. AQR Capital Management LLC lifted its position in shares of Medifast by 14.5% in the 1st quarter. AQR Capital Management LLC now owns 199,750 shares of the specialty retailer’s stock valued at $2,693,000 after acquiring an additional 25,366 shares in the last quarter. Man Group plc boosted its stake in Medifast by 0.6% in the 2nd quarter. Man Group plc now owns 198,156 shares of the specialty retailer’s stock worth $2,784,000 after purchasing an additional 1,200 shares during the period. Ameriprise Financial Inc. boosted its stake in Medifast by 9.0% in the 2nd quarter. Ameriprise Financial Inc. now owns 76,801 shares of the specialty retailer’s stock worth $1,079,000 after purchasing an additional 6,322 shares during the period. Finally, Bridgeway Capital Management LLC grew its position in Medifast by 164.6% during the 2nd quarter. Bridgeway Capital Management LLC now owns 57,944 shares of the specialty retailer’s stock worth $814,000 after purchasing an additional 36,044 shares in the last quarter. 95.51% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of Medifast in a report on Saturday. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Medifast presently has a consensus rating of “Reduce” and a consensus price target of $16.50.

Medifast Company Profile

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.